IR501 data

IMNR announced that Phase II testing showed statistically significant improvements according to the ACR 20 criteria of the American College of Rheumatology. The low dose tested, 90 µg, was given to 31 patients, and 300 µg was given to 35 patients, while 33 patients served as a control. None of the patients withdrew due to adverse events related to the treatment.

A single injection into muscle was given at weeks 0, 4, 8, and 20 of the trial. After the third injection, 56 percent of treated patients on the 90 µg dose improved by the ACR 20 criteria, compared to 19 percent of the controls. After the fourth injection, 50 percent on the 90 µg dose had improved versus 19 percent of controls. ...